{
    "clinical_study": {
        "@rank": "109161", 
        "arm_group": [
            {
                "arm_group_label": "Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel", 
                "arm_group_type": "Experimental", 
                "description": "Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.)"
            }, 
            {
                "arm_group_label": "Duac\u00ae Topical Gel", 
                "arm_group_type": "Active Comparator", 
                "description": "Duac\u00ae (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel)"
            }, 
            {
                "arm_group_label": "Placebo Topical Gel", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.)"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to compare the relative efficacy and safety of the test\n      formulation Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) to\n      the marketed formulation Duac\u00ae Topical Gel (Clindamycin 1%/Benzoyl Peroxide 5%) (Stiefel) in\n      the treatment of the inflamed lesions of acne vulgaris. Both the test and reference\n      formulations will also be compared to a placebo formulation to test for superiority."
        }, 
        "brief_title": "A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac\u00ae Topical Gel in the Treatment of Acne Vulgaris", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Acne Vulgaris", 
        "condition_browse": {
            "mesh_term": "Acne Vulgaris"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or non-pregnant, non-lactating female, between 12 and  40 years of age with a\n             clinical diagnosis of acne vulgaris.\n\n          -  Signed informed consent form. For a minor, the parent or legal guardian will sign the\n             consent form and patient will sign assent to participate form.\n\n          -  If female of child-bearing potential, prepare to abstain from sexual intercourse or\n             use a reliable method of contraception during the study. Patients on hormonal\n             contraceptives must have been on the same for three months prior to baseline visit\n             and continue throughout the duration of the study.\n\n          -  Have facial acne with 20 or more facial inflammatory lesions and 25 or more\n             non-inflammatory lesions and 2 or less nodulocystic lesions and have an Investigator\n             Global Assessment score of 2, 3 or 4.\n\n          -  Willing to comply with the study requirements and restrictions including refraining\n             from the use of all other topical acne medications or antibiotics during the\n             treatment period.\n\n        Exclusion Criteria:\n\n          -  Patient has more than 2 facial nodular lesions.\n\n          -  Patient has active cystic acne.\n\n          -  Patient has acne conglobata.\n\n          -  Patients with excessive facial hair that would interfere with the diagnosis or\n             assessment of acne.\n\n          -  Patients with tatoos or excessive facial scarring that may interfere with the\n             evaluation of the patient's acne.\n\n          -  Patients with active facial sunburn, peeling due to sunburn and patients who will be\n             exposed to excessive sunlight during the study.\n\n          -  Any skin condition other than acne vulgaris that would interfere with the evaluation\n             of the patient's acne.\n\n          -  Females who are pregnant, lactating or likely to become pregnant during the study.\n\n          -  Patients with a history of or active colitis other than irritable bowel syndrome.\n\n          -  History of allergy or hypersensitivity to Clindamycin, Lincomycin or benzoyl peroxide\n             or history of any drug hypersensitivity or intolerance which would compromise the\n             patient's safety or the study.\n\n          -  Significant history or current evidence of chronic infectious disease, system\n             disorder, organ disorder or other medical condition that would place the patient at\n             undue risk by participation.\n\n          -  Use on the face within 1 month prior to screening/baseline or during the study of the\n             following: cryodestruction or chemodestruction, dermabrasion, photodynamic therapy,\n             acne surgery, intralesional steroids, x-ray therapy.\n\n          -  Use of the following within 1 month prior to screening/baseline: spironolactone,\n             systemic steroids, systemic antibiotics, systemic treatment for acne vulgaris (other\n             than oral retinoids which require a 6 month washout), systemic anti-inflammatory\n             agents.\n\n          -  Use of oral isotretinoin (Accutane\u00ae) or oral retinoids within 6 months, or\n             therapeutic vitamin A supplements greater than 10,000 units/day.\n\n          -  Use within 2 weeks prior to screening/baseline of the following: topical steroids,\n             topical retinoids, topical acne treatments including over-the-counter preparations,\n             topical anti-inflammatory agents, medicated cleansers, topical antibiotics.\n\n          -  Receipt of any drug as part of a research study within 30 days.\n\n          -  Female patients taking hormonal contraceptives or oral estrogen for less than 3\n             months and those that plan to change the dosage regimen during the course of the\n             study.\n\n          -  Previous participation in this study.\n\n          -  Employees of the investigator or research center or their immediate family members."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "650", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01769664", 
            "org_study_id": "CLBG 1209"
        }, 
        "intervention": [
            {
                "arm_group_label": "Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel", 
                "description": "Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)", 
                "intervention_name": "Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Duac\u00ae Topical Gel", 
                "description": "Duac\u00ae (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel) applied once a day in the evening for 77 days (11 weeks)", 
                "intervention_name": "Duac\u00ae Topical Gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Topical Gel", 
                "description": "Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)", 
                "intervention_name": "Placebo Topical Gel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Benzoyl Peroxide", 
                "Clindamycin", 
                "Clindamycin-2-phosphate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Acne vulgaris", 
            "Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel", 
            "Duac\u00ae Topical Gel"
        ], 
        "lastchanged_date": "January 19, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) to Duac\u00ae Topical Gel Clindamycin 1%/Benzoyl Peroxide 5% (Stiefel) in the Treatment of Acne Vulgaris", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Bioequivalence will be determined by evaluating the mean percent change from baseline to week 11 in the number of inflammatory lesions.", 
            "measure": "Bioequivalence of test gel to reference gel", 
            "safety_issue": "No", 
            "time_frame": "Week 11 (study day 77)"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01769664"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The superiority of the test and reference against the placebo will be tested for the mean percent reduction in inflamed lesion count at week 11.", 
            "measure": "Superiority against placebo", 
            "safety_issue": "No", 
            "time_frame": "Week 11 (study day 77)"
        }, 
        "source": "Taro Pharmaceuticals USA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Taro Pharmaceuticals USA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}